Immunoglobulins in COVID-19 pneumonia: from the acute phase to the recovery phase

COVID-19 pneumonia causes hyperinflammatory response that culminates in acute respiratory syndrome (ARDS) related to increased multiorgan dysfunction and mortality risk. Antiviral-neutralizing immunoglobulins production reflect the host humoral status and illness severity, and thus, immunoglobulin (...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medical research 2024-04, Vol.29 (1), p.223-223, Article 223
Main Authors: Peraire, Joaquim, García-Pardo, Graciano, Chafino, Silvia, Sánchez, Alba, Botero-Gallego, Maryluz, Olona, Montserrat, Espineira, Sonia, Reverté, Laia, Skouridou, Vasso, Peiró, Óscar M, Gómez-Bertomeu, Fréderic, Vidal, Francesc, O' Sullivan, Ciara K, Rull, Anna
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Antiviral agents
Bacterial pneumonia
Calibration
COVID-19
COVID-19 pneumonia
Development and progression
Enzymes
Health aspects
Hypertension
IgA
IgG
IgM
Illnesses
Immunoglobulin A
Immunoglobulin G
Immunoglobulins
Infections
Intubation
Mortality
Pandemics
Pneumonia
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Spain
Taiwan
Ventilators
Viral infections
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:COVID-19 pneumonia causes hyperinflammatory response that culminates in acute respiratory syndrome (ARDS) related to increased multiorgan dysfunction and mortality risk. Antiviral-neutralizing immunoglobulins production reflect the host humoral status and illness severity, and thus, immunoglobulin (Ig) circulating levels could be evidence of COVID-19 prognosis. The relationship among circulating immunoglobulins (IgA, IgG, IgM) and COVID-19 pneumonia was evaluated using clinical information and blood samples in a COVID-19 cohort composed by 320 individuals recruited during the acute phase and followed up to 4 to 8 weeks (n = 252) from the Spanish first to fourth waves. COVID-19 pneumonia development depended on baseline Ig concentrations. Circulating IgA levels together with clinical features at acute phase was highly associated with COVID-19 pneumonia development. IgM was positively correlated with obesity (ρb = 0.156, P = 0.020), dyslipemia (ρb = 0.140, P = 0.029), COPD (ρb = 0.133, P = 0.037), cancer (ρb = 0.173, P = 0.007) and hypertension (ρb = 0.148, P = 0.020). Ig concentrations at recovery phase were related to COVID-19 treatments. Our results provide valuable information on the dynamics of immunoglobulins upon SARS-CoV-2 infection or other similar viruses.
ISSN:2047-783X
0949-2321
2047-783X
DOI:10.1186/s40001-024-01824-5